Patients with primary sclerosing cholangitis with and without end-stage liver disease have similar outcomes after liver transplantation

Table 2 Univariate and multivariate analyses of risk factors for recurrence of primary sclerosing cholangitis

Characteristic	Univariable				Multivariable
	n	HR	95%CI	P value	HR	95%CI	P value
Age at LT	131	0.99	0.96-1.01	0.4	0.99	0.96-1.02	0.5
Sex	131	-	-	-	-	-	-
Female	-	-	-	-	-	-	-
Male	-	1.17	0.59-2.31	0.7	1.23	0.54-2.78	0.6
Overlap PSC/AIH	131	1.54	0.80-2.95	0.2	2.13	0.87-5.21	0.1
IBD before LT	131	1	0.52-1.91	> 0.9	1.05	0.50-2.17	> 0.9
Liver cirrhosis	131	1.78	0.70-4.52	0.2	2.34	0.82-6.69	0.11
Decompensation of liver cirrhosis	131	0.96	0.53-1.74	0.9	0.84	0.32-2.17	0.7
Child-Pugh score prior to LT	131	1.09	0.94-1.26	0.3	-	-	-
MELD prior to LT	131	1.03	0.98-1.09	0.2	1	0.93-1.07	> 0.9
End-stage liver disease indication	131	0.92	0.51-1.66	0.8	1.04	0.39-2.73	> 0.9
Split or reduced liver graft	131	2.42	0.93-6.26	0.07	5	1.62-15.4	0.005
Donor type	131	-	-	-	-	-	-
DBD-ECD	-	-	-	-	-	-	-
DBD-SCD	-	0.62	0.31-1.25	0.2	1.06	0.45-2.49	0.9
Donor-recipient sex missmatch	131	1.37	0.76-2.49	0.3	1.65	0.78-3.52	0.2
Cyclosporine	131	0.52	0.20-1.33	0.2	0.4	0.13-1.27	0.12
Duct-to-duct anastomosis	131	1.32	0.70-2.47	0.4	0.91	0.41-2.03	0.8
Episode of ACR	131	1.19	0.66-2.15	0.6	1.08	0.52-2.26	0.8
Multiple episodes of ACR	131	2.28	1.06-4.91	0.036	3.95	1.44-10.8	0.008
CMV infection	131	2.1	1.14-3.89	0.018	2.16	1.05-4.46	0.037
Length of hospitalization	131	1.01	1.00-1.03	0.12	1.02	1.01-1.04	0.009

ACR: Acute cellular rejection; AIH: Autoimmune hepatitis; CI: Confidence interval; CMV: Cytomegalovirus; DBD: Donation after brain death; ECD: Expanded criteria donor; HR: Hazard ratio; IBD: Inflammatory bowel disease; LT: Liver transplantation; MELD: Model for end-stage liver disease; PSC: Primary sclerosing cholangitis; SCD: Standard criteria donor.